facebook twitter linkedin
rd offer

This material was prepared by a third party towards Selvita S.A. with its registered office in Kraków (hereunder: “Selvita”). Within the scope which was not authorized by Selvita’s management board, the description of factual circumstances regarding the activities of Selvita, embodied in this material presents merely opinion of the third party, in particular with respect to presented opinions, predictions, appraisals and forecasts of the financial data and future activity of Selvita and its results.

Therefore, Selvita does not warrant consistency of this material with the actual and legal situation. Neither Selvita, members of its corporate bodies, employees nor its consultants shall bear any liability for validity of opinions, predictions, appraisals, forecasts and any other date embodied in this material as well as for consequences of actions of any reader made on a basis of this material, in particular for the investment decisions or any losses resulting from use of this material.

Readers of this material shall make its own assessment, whether opinions or forecasts embodied therein are credible and adequate, in particular taking into account their investment strategy and actual and legal situation. In particular they should consult it with their independent financial and investment advisors. None of the information presented in this material shall constitute investment, legal, accounting or tax advice or a statement that any investment strategy is accurate or adequate, considering the circumstances of the reader.

Furthermore date presented in this material shall not constitute an offer to sell or purchase any financial instruments nor an invite the make such offer. It shall not be also not deemed as a recommendation for investment in any financial instrument nor an advertisement of such instruments.


SEL24 program

The goal of SEL24 project is to develop innovative anticancer drug acting by ability to selectively destroy cancer cells. Within the SEL24 project Selvita discovered specific, dual PIM/FLT3 inhibitors, shown to be key players in signaling pathways crucial for the development of different type of cancers – mainly acute myeloid leukemia but also other hematological malignancies.

Our best inhibitor, SEL24-B489, shows high anti-cancer efficacy in both in vitro models using cancer cell lines and in vivo including mouse models of human cancer cell lines xenografts. In our experiments we observed a synergism of our compound with established standards of care, such as cytarabine, further confirming therapeutic potential of our compound in a combinational therapy. On the top of these data, SEL24-B489 shows superior activity on panel of AML (acute myeloid leukemia) models in comparison to other selective PIM or FLT3 inhibitors currently developed by competitors. SEL24-B489 is a bioavailable compound showing promising safety profile, supported by initial data in animal models.

In August 2016, FDA has accepted Selvita's IND application for the SEL24 Phase I/II clinical trial in AML.

Clinical development of the program is planned for Q4 2016.